Study | No. of patients | Design | Type of treatment | CR (%) | PR (%) | Median survival (months) | 1-y OS (%) |
Our study | 62 | Prospective | 3DCRT to PVTT | 8.5% | 31.9% | All patients: 8.2 Responders: 12.5 Non responders: 8 | All patients: 25.2 Responders: 56.5 Non responders: 17.2 |
Rim et al. (2012) | 45 | Retrospective | 3DCRT to PVTT ± Liver tumor | 6.7% | 55.6% | All patients: 11.2 Responders: 16.7 Non responders: 8 | Responders: 63.7 Non responders: 28 |
Hou et al. (2012) | 128 | Retrospective | 3DCRT to PVTT | 20.8% | 33.3% | 8.2 | - |
Huang et al. (2009) | 326 | Retrospective | 3DCRT/IMRT to PVTT | 5.8% | 19.4% | All patients: 4 CR: 13.3 PR: 11.6 SD: 9 PD: 4.5 | - |
Toya et al. (2007) | 38 | Retrospective | 3DCRT to PVTT ± Liver tumor | 15.8% | 28.9% | 9.6 | 39.4 |
Lin et al. (2006) | 22/21 | Prospective | SBRT/3DCRT to PVTT | Crude response 75%/83% | 6/6.7 | - | |
Kim et al. (2005) | 59 | Retrospective | 3DCRT to PVTT and Liver tumor | 6.8% | 39% | Responders: 10.7 Non responders: 5.3 | Responders: 40.7 Non responders: 25 |